The treatment has gained approval in the European Union (EU) for a range of conditions, including psoriatic arthritis, ...

A key regulatory win could turn this under-the-radar treatment into AbbVie's next billion-dollar success story.

Hyderabad: Biological E. Limited has announced a strategic partnership with Bavarian Nordic A/S to expand access to Bavarian ...

Vertex Pharmaceuticals (NASDAQ:VRTX) announced Friday that an expert panel of the EU drug regulator, the European Medicines ...

If approved, this off-the-shelf, fixed-duration Columvi combination will be the first bispecific antibody regimen available for patients with DLBCL following relapse ...

February brought policy updates and several biosimilar approvals, including the first FDA approval for an insulin aspart ...

About Fabhalta® (iptacopan) Fabhalta (iptacopan) is an oral, Factor B inhibitor of the alternative complement pathway 6-7.

Developed by Johnson & Johnson, guselkumab (GUS) is the first approved fully-human, dual-acting IL-23p19 subunit inhibitor that blocks IL-23 and binds to CD64, a receptor on cells that produce IL-23.

The latest UN human rights report urges an end to forced psychiatric treatment as U.S. mental health hospitals face ...